Flinspach, Armin Niklas
Raimann, Florian Jürgen
Kaiser, Philipp
Pfaff, Michaela
Zacharowski, Kai
Neef, Vanessa
Adam, Elisabeth Hannah
Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluation of volatile sedation in the postoperative intensive care of patients recovering from heart valve surgery: protocol for a randomised, controlled, monocentre trial
https://doi.org/10.1136/bmjopen-2021-057804
Volatile versus propofol sedation after cardiac valve surgery: a single-center prospective randomized controlled trial
https://doi.org/10.1186/s13054-024-04899-y
Funding for this research was provided by:
Sedana Medical SE (Sedana Medical Research Grant 2020)
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Received: 29 January 2024
Accepted: 3 April 2024
First Online: 5 April 2024
Declarations
:
: The protocol was approved by the ethics committee of the Goethe University Frankfurt am Main (#20-1050) and registered at clinicaltrials.gov on the 1st of July 2021 (NCT04958668) before the first patient enrollment. An informed consent was obtained from each individual patient or their legal representative in advance.
: Not applicable.
: A.N.F. received speaker fees from P.J. Dahlhausen & Co. GmbH, Cologne, Germany, received the Sedana Medical Research Grant 2020 and Thieme Teaching Award 2022. E.H.A. received a research Grant from the German Research Foundation (AD 592/1-1). F.J.R. received speaker fees from Helios Germany, university hospital Würzburg and Keller Medical GmbH. FJR received financial support by HemoSonics LLC, pharma-consult Petersohn and Boehringer Ingelheim. V.N. received speaker fees from Sysmex and Pharmacosmos. K.Z. has received honoraria for participation in advisory board meetings for Haemonetics and Vifor and received speaker fees from CSL Behring, Masimo, Pharmacosmos, Boston Scientific, Salus, iSEP, Edwards and GE Healthcare. He is the Principal Investigator of the EU-Horizon 2020 project ENVISION (Intelligent plug-and-play digital tool for real-time surveillance of COVID-19 patients and smart decision-making in Intensive Care Units) and Horizon Europe 2021 project COVend (Biomarker and AI-supported FX06 therapy to prevent progression from mild and moderate to severe stages of COVID-19). The Department of Anaesthesiology, Intensive Care Medicine & Pain Therapy of the University Hospital Frankfurt, Goethe University received support from B. Braun Melsungen, CSL Behring, Fresenius Kabi, and Vifor Pharma for the implementation of Frankfurt’s Patient Blood Management program. M.P. and P.K. declare that there are no competing interests.